Transforming growth factor β3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis

Experimental Hematology

Volumn 28, Issue 7, 2000, Pages 775-783

  Fogli, Miriam ^a   Carlo Stella, Carmelo ^c   Curti, Antonio ^a   Ratta, Marina ^a   Tazzari, Pierluigi ^b   Ragazzi, Ester ^c   Colla, Simona ^c   Santucci, Alessandra M ^a   Tura, Sante ^a   Lemoli, Roberto M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Apoptosis; Chronic myelogenous leukemia; Stem cells; Transforming growth factor

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; FAS ANTIGEN; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 3; RECOMBINANT STEM CELL FACTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL SPECIFICITY; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; CONTROLLED STUDY; DONOR; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; STEM CELL;

ANTIGENS, CD34; ANTIGENS, CD95; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CLONE CELLS; CYTOKINES; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 0034085552     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00173-9     Document Type: Article

References (43)

1. Massague J. The transforming growth factor-β family. Ann Rev Cell Biol. 6:1990;597.
2. Jacobsen S.E.W., Keller J.R., Ruscetti F.W.et al. Bidirectional effects of transforming growth factor β (TGF-β) on colony-stimulating factor-induced human myelopoiesis in vitro. differential effects of distinct TGF-β isoforms Blood. 78:1991;2239.
3. 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood. Cancer Res. 15:1991;4828.
4. 3. J Immunol. 151:1993;4534.
5. 3) on human primitive hematopoietic progenitor cells. Haematologica. 80:1995;5.
6. Eaves C.J., Eaves A.C. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro. Blood Cells. 20:1994;83.
7. Cashman J.D., Eaves A.C., Eaves C.J. Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-beta on normal and leukemic human hematopoietic progenitor cells. Leukemia. 9:1992;886.
8. Holyoake T.L., Freshney M.G., Sproul A.M.et al. Contrasting effects of rh-MIP1 α and TGF-β1 on chronic myeloid leukemia progenitors in vitro. Stem Cells. 11(suppl. 3):1993;122.
9. Cashman J.D., Eaves C.J., Sarris A.H.et al. MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood. 92:1998;2338.
10. Jacobsen S.E.W., Ruscetti F.W., Dubois C.M.et al. Transforming growth factor-β trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood. 77:1991;1706.
11. Laiho M., Di Caprio J.A.et al. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell. 62:1990;175.
12. Takehara K., Le Roy E.C.et al. TGF-β inhibition of endothelial cell proliferation. alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression Cell. 49:1987;415.
13. Dubois C.M., Ruscetti F.W., Stankova J.et al. Transforming growth factor-β regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. Blood. 83:1994;3138.
14. Ploemacher R.E., van Soest P.L., Boudewijn A. Autocrine transforming growth factor β1 blocks colony formation and progenitor cell generation by hemopoietic stem cells stimulated with steel factor. Stem Cells. 11:1993;336.
15. 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Exp Hematol. 20:1992;1252.
16. 3 protection of epithelial cells from cycle-selective chemotherapy in vitro. Biochem Pharmacol. 53:1997;1149.
17. Potten C.S., Booth D., Haley J.D. Pretreatment with transforming growth factor β-3 protects small intestinal stem cells against radiation damage in vivo. Br J Cancer. 75:1997;1454.
18. Lotem J., Sachs L. Hematopoietic cytokines inhibits apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood. 80:1992;1750.
19. Weller M., Frei K., Groscurth P.et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest. 94:1994;954.
20. Jacobsen F.W., Stokke T., Jacobsen S.E.W. Transforming growth factor-β potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Blood. 86:1995;2957.
21. Dybedal I., Guan F., Borge O.J.et al. Transforming growth factor-β1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells. Blood. 90:1997;3395.
22. Riedl E., Strobl H., Majdic O.et al. TGF-β1 promotes in vitro generation of dendritic cells by protecting progenitor cells from apoptosis. J Immunol. 158:1997;1591.
23. Itoh N., Yonehara S., Ishii S.et al. The polypeptide sequence encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233.
24. Beutler B., van Huffel C.H. Unraveling function in the TNF ligand and receptor families. Science. 264:1994;667.
25. Suda T., Takahashi T., Golstein P.et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169.
26. Owen-Schaub L.B., Yonehara S., Crump W.L.et al. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 140:1993;197.
27. Alderson M.R., Armitage R.J., Maraskowsky E.et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 178:1993;2232.
28. Selleri C., Sato T., Del Vecchio L.et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood. 89:1997;957.
29. + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183.
30. Selleri C., Maciejwski J.P., Pane F.et al. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 92:1998;981.
31. Bedi A., Zehnbauer B.A., Barber J.P.et al. Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood. 83:1994;2038.
32. McGahon A., Bissonette R., Schmitt M.et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1994;1179.
33. + cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood. 89:1997;1189.
34. Fogli M., Amabile M., Martinelli G.et al. Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. Br J Haematol. 101:1998;119.
35. Carlo-Stella C., Dotti G., Mangoni L.et al. Selection of myeloid progenitors lacking BCR-ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood. 88:1996;3091.
36. Koopman G., Reutelingsperger C.P., Kuijten G.A.et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415.
37. Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 15:1995;5531.
38. Druker B.J., Tamura S., Buchdunger E.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561.
39. Friesen C., Herr I., Krammer P.H.et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 2:1996;574.
40. Gora-Tybor J., Deininger M.W.M., Goldman J.M.et al. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol. 103:1998;716.
41. Wickremasinghe R.G., Hoffbrand V.A. Biochemical and genetic control of apoptosis. relevance to normal hematopoiesis and hematological malignancies Blood. 93:1999;3587.
42. Beka C., Marini P., Lepple-Wienhues A.et al. The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene. 18:1999;4983.
43. + chronic myelogenous leukemia progenitor cells. Blood. 93:1999;3973.